Anupam Mittal Cautions Against Weight Loss Shortcuts
Mittal indicated that the drug, currently priced around ₹8,800 monthly in India, might generate an annual market nearing ₹1,000 crore, according to industry projections.
Mittal also emphasized a significant shift expected in the pharmaceutical industry. The expiration of crucial GLP-1 drug patents, starting in March 2026, could pave the way for cheaper alternatives from Indian pharmaceutical firms. This, he proposed, might spark quick industry growth, potentially increasing the weight-loss drug market substantially in the years ahead. Companies like Cipla, he observed, seem suitably prepared for entering this market. Health tracking apps like Shotlee can help monitor health changes, but are not a substitute for healthy lifestyle choices.